Real-life experience with transvaginal radiofrequency ablation in infertile patients with types 2 and 3 fibroids

IF 3.9 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Reproductive biomedicine online Pub Date : 2026-01-01 Epub Date: 2025-06-14 DOI:10.1016/j.rbmo.2025.105104

María Cerrillo , Javier Martínez-Salazar , Cristina Fernández , Pedro Royo , Alberto Vázquez , Elkin Muñoz , Víctor H. Gómez , José Puente , Antonio Requena , Juan A. García-Velasco

{"title":"Real-life experience with transvaginal radiofrequency ablation in infertile patients with types 2 and 3 fibroids","authors":"María Cerrillo , Javier Martínez-Salazar , Cristina Fernández , Pedro Royo , Alberto Vázquez , Elkin Muñoz , Víctor H. Gómez , José Puente , Antonio Requena , Juan A. García-Velasco","doi":"10.1016/j.rbmo.2025.105104","DOIUrl":null,"url":null,"abstract":"<div><h3>Research question</h3><div>Transvaginal radiofrequency ablation (TRFA) may offer a safe and effective alternative to surgery for infertile women with type 2 or 3 fibroids under 4 cm diameter that compromise the uterine cavity.</div></div><div><h3>Methods</h3><div>In this study, 36 patients underwent ultrasound-guided TRFA between 2020 and 2023. Main outcomes were fibroid volume reduction at 1, 3, and 6 months, and post-procedure reproductive results.</div></div><div><h3>Results</h3><div>Mean baseline fibroid volume was 19.29 cm<sup>3</sup>, decreasing to 9.6 cm<sup>3</sup> at 1 month, 4.39 cm<sup>3</sup> at 3 months, and 4.07 cm<sup>3</sup> at 6 months, reflecting >75% reduction. Mild pain and minimal bleeding occurred in 22% of patients; hysteroscopic removal of protruding fibroids was required in 22%. Among the 25 women undergoing subsequent ART, pregnancy and miscarriage rates per treated patient were 68% and 16%, respectively; live births occurred in 52%, with most deliveries at full-term. Caesarean delivery rate was 69.2%.</div></div><div><h3>Conclusions</h3><div>TRFA appears to be a safe and effective alternative to surgery for infertile women with type 2 or 3 fibroids under 4 cm in diameter that compromise the uterine cavity. The procedure does not seem to affect reproductive outcomes, and this study is the first to assess the effect of TRFA on ART.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 1","pages":"Article 105104"},"PeriodicalIF":3.9000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive biomedicine online","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1472648325003116","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Research question

Transvaginal radiofrequency ablation (TRFA) may offer a safe and effective alternative to surgery for infertile women with type 2 or 3 fibroids under 4 cm diameter that compromise the uterine cavity.

Methods

In this study, 36 patients underwent ultrasound-guided TRFA between 2020 and 2023. Main outcomes were fibroid volume reduction at 1, 3, and 6 months, and post-procedure reproductive results.

Results

Mean baseline fibroid volume was 19.29 cm³, decreasing to 9.6 cm³ at 1 month, 4.39 cm³ at 3 months, and 4.07 cm³ at 6 months, reflecting >75% reduction. Mild pain and minimal bleeding occurred in 22% of patients; hysteroscopic removal of protruding fibroids was required in 22%. Among the 25 women undergoing subsequent ART, pregnancy and miscarriage rates per treated patient were 68% and 16%, respectively; live births occurred in 52%, with most deliveries at full-term. Caesarean delivery rate was 69.2%.

Conclusions

TRFA appears to be a safe and effective alternative to surgery for infertile women with type 2 or 3 fibroids under 4 cm in diameter that compromise the uterine cavity. The procedure does not seem to affect reproductive outcomes, and this study is the first to assess the effect of TRFA on ART.

查看原文本刊更多论文

经阴道射频消融治疗2型和3型肌瘤不孕患者的实际经验

研究问题：对于2型或3型肌瘤直径小于4厘米且危及子宫腔的不孕妇女，经阴道射频消融（TRFA）可能是一种安全有效的替代手术的方法。方法在本研究中，36例患者在2020年至2023年期间接受了超声引导下的TRFA。主要结果是1、3和6个月时肌瘤体积减少，以及术后生殖结果。结果平均基线肌瘤体积为19.29 cm3, 1个月时降至9.6 cm3, 3个月时降至4.39 cm3, 6个月时降至4.07 cm3，缩小了75%。22%的患者出现轻度疼痛和少量出血；22%的患者需要宫腔镜切除突出的肌瘤。在随后接受抗逆转录病毒治疗的25名妇女中，每名接受治疗的患者的怀孕率和流产率分别为68%和16%；52%为活产，多数为足月分娩。剖宫产率为69.2%。结论strfa对于直径小于4cm的2型或3型肌瘤累及子宫腔的不孕症患者是一种安全有效的手术治疗方法。该过程似乎不影响生殖结果，本研究首次评估TRFA对ART的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reproductive biomedicine online 医学-妇产科学

CiteScore

7.20

自引率

7.50%

发文量

391

审稿时长

50 days

期刊介绍： Reproductive BioMedicine Online covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients. Context: The period of human embryonic growth covered is between the formation of the primordial germ cells in the fetus until mid-pregnancy. High quality research on lower animals is included if it helps to clarify the human situation. Studies progressing to birth and later are published if they have a direct bearing on events in the earlier stages of pregnancy.